Core Viewpoint - Jin Hai Medical Technology (02225) announced a capital contribution agreement to increase the registered capital of Jin Hai Biomedical from RMB 5 million to RMB 25 million, with additional funding of RMB 20 million from Shanghai Jin Hai and Shanghai Anbida Investment based on their respective shareholding ratios of 51:49 [1] Group 1 - The capital increase aims to enhance the capital strength of Jin Hai Biomedical to support its business development, focusing on the wholesale and distribution of medical devices [1] - The funding amount was determined through fair negotiation between Jin Hai Biomedical and its shareholders, considering the short-term funding needs for business development and investment opportunities [1] - Jin Hai Biomedical will continue to be accounted for as a non-wholly-owned subsidiary in the group's financial statements, regardless of the capital contribution [1]
今海医疗科技附属今海生物医疗拟获2000万元增资